About this book
Summary
Indifferent Diagnosis: The Health of BioPharma in 2025 is your inside pass to an industry running at two speeds—record-breaking M&A on one end, widespread cash-burn triage on the other. Veteran strategist Frank Dolan unpacks why 40 % of public biotechs are months from insolvency while giants like Pfizer and Novartis spend billions on de-risked assets; how AI, CRISPR, and next-gen delivery tech are redrawing drug-discovery maps; and where regulatory, demographic, and private-equity cross-currents will push the market next. Packed with hard data, boardroom stories, and survival playbooks, this audiobook arms executives, investors, and scientists with the context—and contrarian edge—needed to navigate 2025’s most volatile sector.Book information
Rating
★★★★★ (5.0) (3)
Genre
Business and Economics
Length
2 hrs 35 mins
Publish date
Jun 25, 2025
Language
English
About the Author
Frank F. Dolan
Table of Contents
1Introduction
12Chapter 11: Therapeutic Focus Areas in 2025
2Chapter 1: The State of Biopharma in 2025
13Chapter 12: The Role of Technology in Driving Innovation
3Chapter 2: M&A Activity: A Boon and a Burden
14Chapter 13: Regional Trends and Cross-Border Activities
4Chapter 3: Understanding Financial Distress in Biotech Companies
15Chapter 14: Understanding Risk Factors and Managing Market Volatility
5Chapter 4: The IPO Market: Is the Opportunity Shrinking?
16Chapter 15: The Future of Drug Development and Innovation